Veterinary Active Pharmaceutical Ingredients Manufacturing Market Size, Share | Research Report [2030]
The global Veterinary Active Pharmaceutical Ingredients Manufacturing market gathered revenue around USD 8.2 billion in 2021 and market is set to grow USD 12.9 billion by the end of 2030 and is estimated to expand at a modest CAGR of 6.9% during the prediction period 2022 to 2030.
Growth Factors:
The increasing number of oral formulations for various veterinary drugs is boosting the demand for veterinary Active Pharmaceutical Ingredients (APIs). These majorly include nonsteroidal anti-inflammatory drugs. Manufacturers are investing in process synthesis, which helps in accelerating the manufacturing process for active pharmaceutical ingredients. Furthermore, the introduction of biologically synthesized and high potency APIs, which act on the target cells with a much lower dose as compared to the general APIs, is also expected to support market growth.
Market players are consistently striving to achieve desired profit margins through geographical expansion. For instance, in November 2020, Ofichem Group expanded with a new office in Hangzhou, China. This supported the company’s growth strategy. In May 2018, Zoetis expanded its manufacturing and supply facility in Kalamazoo to provide high-quality medicines for veterinarian and livestock farmer customers.
Favorable government policies are boosting the manufacturing of veterinary active pharmaceutical ingredients. For instance, initiatives, such as Pharma Vision 2020 by the Indian government, which is aimed at developing the country’s capabilities in the fields of drug discovery, innovation, and drug manufacturing, is expected to have a positive impact on the political scenario of the market. This is expected to fuel the market growth.
This research report purposes at stressing the most lucrative growth prospects. The aim of the research report is to provide an inclusive valuation of the Veterinary Active Pharmaceutical Ingredients Manufacturing market and it encompasses thoughtful visions, actualities, industry-validated market findings, historic data, and prognoses by means of appropriate set of assumptions and practice. Global Veterinary Active Pharmaceutical Ingredients Manufacturing market report aids in comprehending market structure and dynamics by recognizing and scrutinizing the market sectors and predicted the global market outlook.
Report Coverage
| Report Scope | Details |
| Market Size | USD 12.9 billion by 2030 |
| Growth Rate | CAGR of 6.9% From 2022 to 2030 |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Report coverage | Growth Factors, Revenue Status, Competitive Landscape, and Future Trends |
| Segments Covered | Service type, synthesis type, product Region Type |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA) |
| Companies Mentioned | Alivira Animal Health Ltd.; Excel Industries Ltd.; Ofichem Group; Shaanxi Hanjiang Pharmaceutical Group Co., Ltd.; Menadiona; Afton Pharma; Jiangsu Lingyun Pharmaceutical Co., Ltd.; SUANFARMA; NGL Fine-Chem Ltd.; FIS - Fabbrica Italiana Sintetici SPA. |
COVID-19 Impact Assessment on Market Landscape
The report comprises the scrutiny of COVID-19 lock-down impact on the income of market leaders, disrupters and followers. Since lock down was instigated differently in diverse regions and nations, influence of same is also dissimilar across various industry verticals. The research report offers present short-term and long-term influence on the market to assist market participants across value chain makers to formulate the framework for short term and long-lasting tactics for recovery and by region.
Veterinary Active Pharmaceutical Ingredients Manufacturing market Report empowers readers with all-inclusive market intelligence and offers a granular outline of the market they are operational in. Further this research study delivers exceptional combination of tangible perceptions and qualitative scrutiny to aid companies accomplishes sustainable growth. This report employs industry-leading research practices and tools to assemble all-inclusive market studies, intermingled with pertinent data. Additionally, this report also emphases on the competitive examination of crucial players by analyzing their product portfolio, pricing, gross margins, financial position, growth approaches, and regional occurrence.
Regional Insights
North America was the dominant regional market in 2021 and accounted for a revenue share of over 32.9%. Zoonoses are an additional threat to public health as animals are often the natural source of a disease. The high prevalence of zoonotic diseases is the key factor contributing to the market growth. Favorable reimbursement programs are fueling the demand for veterinary medicine, thereby providing a growth platform for the market in this region.
On the other hand, Asia Pacific is projected to be the fastest-growing regional market from 2022 to 2030. Market growth in the region can be attributed to the significantly high cattle population, which has enhanced the demand for meat production. China and India constitute more than 30.9% of the global cattle population. Moreover, in 2018, Asia Pacific accounted for 40 to 50% of the total meat production worldwide.
Competitive Rivalry
Foremost players in the market are attentive on adopting corporation strategies to enhance their market share. Some of the prominent tactics undertaken by leading market participants in order to sustain the fierce market completion include collaborations, acquisitions, substantial spending in R&D and the improvement of new-fangled products or reforms among others.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
Some of the prominent players in the Veterinary Active Pharmaceutical Ingredients Manufacturing Market include: Alivira Animal Health Ltd.; Excel Industries Ltd.; Ofichem Group; Shaanxi Hanjiang Pharmaceutical Group Co., Ltd.; Menadiona; Afton Pharma; Jiangsu Lingyun Pharmaceutical Co., Ltd.; SUANFARMA; NGL Fine-Chem Ltd.; FIS - Fabbrica Italiana Sintetici SPA
Segments Covered in the Report
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for the period of 2017 to 2030 and covers subsequent region in its scope:
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Highlights of the Report:
Research Methodology
In the study, a unique research methodology is utilized to conduct extensive research on the growth of the Veterinary Active Pharmaceutical Ingredients Manufacturing market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.
Secondary resources referred to by analysts during the production of the Veterinary Active Pharmaceutical Ingredients Manufacturing market study are as follows - statistics from government organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, all of whom have contributed to the development of this report as a primary resource.
Comprehensive information acquired from primary and secondary resources acts as a validation from companies in the market, and makes the projections on the growth prospects of the Veterinary Active Pharmaceutical Ingredients Manufacturing markets more accurate and reliable.
Secondary Research
It involves company databases such as Hoover's: This assists us recognize financial information, structure of the market participants and industry competitive landscape.
The secondary research sources referred in the process are as follows:
Primary Research
Primary research includes face-to face interviews, online surveys, and telephonic interviews.
Industry participants involved in this research study include:
Key Points Covered in Veterinary Active Pharmaceutical Ingredients Manufacturing Market Study:
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Service
7.1. Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Service Type, 2022-2030
7.1.1. In House
7.1.1.1. Market Revenue and Forecast (2019-2030)
7.1.2. Contract Outsourcing
7.1.2.1. Market Revenue and Forecast (2019-2030)
Chapter 8. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Synthesis Type
8.1. Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Synthesis Type, 2022-2030
8.1.1. Chemical-based API
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Biological API
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. HPAPI
8.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Product Type
9.1. Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Product Type, 2022-2030
9.1.1. Antiparasitic
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Anti-infectives
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. NSAIDs
9.1.3.1. Market Revenue and Forecast (2019-2030)
9.1.4. Vaccines
9.1.4.1. Market Revenue and Forecast (2019-2030)
9.1.5. Biologics
9.1.5.1. Market Revenue and Forecast (2019-2030)
9.1.6. Others
9.1.6.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, By Service (2019-2030)
10.1.2. Market Revenue and Forecast, By Synthesis Type (2019-2030)
10.1.3. Market Revenue and Forecast, By Product Type (2019-2030)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, By Service (2019-2030)
10.1.4.2. Market Revenue and Forecast, By Synthesis Type (2019-2030)
10.1.4.3. Market Revenue and Forecast, By Product Type (2019-2030)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, By Service (2019-2030)
10.1.5.2. Market Revenue and Forecast, By Synthesis Type (2019-2030)
10.1.5.3. Market Revenue and Forecast, By Product Type (2019-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, By Service (2019-2030)
10.2.2. Market Revenue and Forecast, By Synthesis Type (2019-2030)
10.2.3. Market Revenue and Forecast, By Product Type (2019-2030)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, By Service (2019-2030)
10.2.4.2. Market Revenue and Forecast, By Synthesis Type (2019-2030)
10.2.4.3. Market Revenue and Forecast, By Product Type (2019-2030)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, By Service (2019-2030)
10.2.5.2. Market Revenue and Forecast, By Synthesis Type (2019-2030)
10.2.5.3. Market Revenue and Forecast, By Product Type (2019-2030)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, By Service (2019-2030)
10.2.6.2. Market Revenue and Forecast, By Synthesis Type (2019-2030)
10.2.6.3. Market Revenue and Forecast, By Product Type (2019-2030)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, By Service (2019-2030)
10.2.7.2. Market Revenue and Forecast, By Synthesis Type (2019-2030)
10.2.7.3. Market Revenue and Forecast, By Product Type (2019-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, By Service (2019-2030)
10.3.2. Market Revenue and Forecast, By Synthesis Type (2019-2030)
10.3.3. Market Revenue and Forecast, By Product Type (2019-2030)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, By Service (2019-2030)
10.3.4.2. Market Revenue and Forecast, By Synthesis Type (2019-2030)
10.3.4.3. Market Revenue and Forecast, By Product Type (2019-2030)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, By Service (2019-2030)
10.3.5.2. Market Revenue and Forecast, By Synthesis Type (2019-2030)
10.3.5.3. Market Revenue and Forecast, By Product Type (2019-2030)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, By Service (2019-2030)
10.3.6.2. Market Revenue and Forecast, By Synthesis Type (2019-2030)
10.3.6.3. Market Revenue and Forecast, By Product Type (2019-2030)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, By Service (2019-2030)
10.3.7.2. Market Revenue and Forecast, By Synthesis Type (2019-2030)
10.3.7.3. Market Revenue and Forecast, By Product Type (2019-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, By Service (2019-2030)
10.4.2. Market Revenue and Forecast, By Synthesis Type (2019-2030)
10.4.3. Market Revenue and Forecast, By Product Type (2019-2030)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, By Service (2019-2030)
10.4.4.2. Market Revenue and Forecast, By Synthesis Type (2019-2030)
10.4.4.3. Market Revenue and Forecast, By Product Type (2019-2030)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, By Service (2019-2030)
10.4.5.2. Market Revenue and Forecast, By Synthesis Type (2019-2030)
10.4.5.3. Market Revenue and Forecast, By Product Type (2019-2030)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, By Service (2019-2030)
10.4.6.2. Market Revenue and Forecast, By Synthesis Type (2019-2030)
10.4.6.3. Market Revenue and Forecast, By Product Type (2019-2030)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, By Service (2019-2030)
10.4.7.2. Market Revenue and Forecast, By Synthesis Type (2019-2030)
10.4.7.3. Market Revenue and Forecast, By Product Type (2019-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, By Service (2019-2030)
10.5.2. Market Revenue and Forecast, By Synthesis Type (2019-2030)
10.5.3. Market Revenue and Forecast, By Product Type (2019-2030)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, By Service (2019-2030)
10.5.4.2. Market Revenue and Forecast, By Synthesis Type (2019-2030)
10.5.4.3. Market Revenue and Forecast, By Product Type (2019-2030)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, By Service (2019-2030)
10.5.5.2. Market Revenue and Forecast, By Synthesis Type (2019-2030)
10.5.5.3. Market Revenue and Forecast, By Product Type (2019-2030)
Chapter 11. Company Profiles
11.1. Alivira Animal Health Ltd.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Excel Industries Ltd.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Ofichem Group
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Shaanxi Hanjiang Pharmaceutical Group Co., Ltd.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Menadiona
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Afton Pharma.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Jiangsu Lingyun Pharmaceutical Co., Ltd.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. SUANFARMA
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. NGL Fine-Chem Ltd.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. FIS - Fabbrica Italiana Sintetici S.p.A
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers